Sven Lichthardt1, Lisa Zenorini2, Johanna Wagner2, Johannes Baur2, Alexander Kerscher3, Niels Matthes2,4, Caroline Kastner2, Jörg Pelz2, Volker Kunzmann3,5, Christoph-Thomas Germer2,3, Armin Wiegering6,7. 1. Department of General, Visceral, Vascular and Pediatric Surgery, University Hospital, Julius-Maximilians-University, University of Wuerzburg, Oberduerrbacherstr.6, 97080, Wuerzburg, Germany. lichthardt_s@ukw.de. 2. Department of General, Visceral, Vascular and Pediatric Surgery, University Hospital, Julius-Maximilians-University, University of Wuerzburg, Oberduerrbacherstr.6, 97080, Wuerzburg, Germany. 3. Comprehensive Cancer Centre Mainfranken, University Hospital, University of Wuerzburg, Josef-Schneiderstr. 6, 97080, Wuerzburg, Germany. 4. Department of Biochemistry and Molecular Biology, University of Wuerzburg, Am Hubland, 97074, Wuerzburg, Germany. 5. Department of Internal Medicine II, University of Wuerzburg Medical Center, Oberduerrbacherstr.2, 97080, Wuerzburg, Germany. 6. Department of General, Visceral, Vascular and Pediatric Surgery, University Hospital, Julius-Maximilians-University, University of Wuerzburg, Oberduerrbacherstr.6, 97080, Wuerzburg, Germany. wiegering_a@ukw.de. 7. Department of Biochemistry and Molecular Biology, University of Wuerzburg, Am Hubland, 97074, Wuerzburg, Germany. wiegering_a@ukw.de.
Abstract
BACKGROUND: Due to its primarily extraperitoneal location, potential affection of the anorectal continence and different metastatic behavior the rectal carcinoma (RC) is classified and treated as an independent disease. Over the past few decades various trials have led to improved multimodal therapies (including radiation, chemotherapy and surgery) for locally advanced rectal cancer and significant changes in the management of this disease whereas the benefit of adjuvant chemotherapy remains unclear. METHODS: Based on a prospective tumor register of the University Hospital of Wuerzburg data of 263 patients having undergone neoadjuvant therapy and surgical resection for locally advanced rectal cancer were retrieved from the Wuerzburg International database (WID) between October 1992 and September 2013 analyzing the overall survival according to the application of an adjuvant therapy. RESULTS: The cohort consisted of 263 patients with a median age of 65 years (27-89 years), mostly male gender (n = 191; 72.6%) and an ASA performance score of II or III. 143 patients (54.3%) received an adjuvant therapy. Those patients have been significant younger (median 10 years; p < 0.05) and in a better general condition (ASA-score; p < 0.05). The tumor specific overall survival of adjuvant treated patients was significant better (5-years overall-survival 87.4%; p = 0.025) than the surveillance group. In the performed subgroup analysis no significant differences in overall survival according to the kind of neoadjuvant therapy (radiation vs. radiochemotherapy) have been found whereas patients in lower UICC-stages (ypUICC 0 + I) had a significant benefit by receiving a postoperative chemotherapy (p = 0.035). CONCLUSION: We considered patients with locally advanced rectal cancer have a significant benefit in overall survival by receiving an adjuvant chemotherapy especially in lower pathological tumor stage (ypUICC 0 + I). Especially because of the heterogeneity of our study population prospective randomized trials are necessary to determine the impact of adjuvant chemotherapy for locally advanced rectal cancer.
BACKGROUND: Due to its primarily extraperitoneal location, potential affection of the anorectal continence and different metastatic behavior the rectal carcinoma (RC) is classified and treated as an independent disease. Over the past few decades various trials have led to improved multimodal therapies (including radiation, chemotherapy and surgery) for locally advanced rectal cancer and significant changes in the management of this disease whereas the benefit of adjuvant chemotherapy remains unclear. METHODS: Based on a prospective tumor register of the University Hospital of Wuerzburg data of 263 patients having undergone neoadjuvant therapy and surgical resection for locally advanced rectal cancer were retrieved from the Wuerzburg International database (WID) between October 1992 and September 2013 analyzing the overall survival according to the application of an adjuvant therapy. RESULTS: The cohort consisted of 263 patients with a median age of 65 years (27-89 years), mostly male gender (n = 191; 72.6%) and an ASA performance score of II or III. 143 patients (54.3%) received an adjuvant therapy. Those patients have been significant younger (median 10 years; p < 0.05) and in a better general condition (ASA-score; p < 0.05). The tumor specific overall survival of adjuvant treated patients was significant better (5-years overall-survival 87.4%; p = 0.025) than the surveillance group. In the performed subgroup analysis no significant differences in overall survival according to the kind of neoadjuvant therapy (radiation vs. radiochemotherapy) have been found whereas patients in lower UICC-stages (ypUICC 0 + I) had a significant benefit by receiving a postoperative chemotherapy (p = 0.035). CONCLUSION: We considered patients with locally advanced rectal cancer have a significant benefit in overall survival by receiving an adjuvant chemotherapy especially in lower pathological tumor stage (ypUICC 0 + I). Especially because of the heterogeneity of our study population prospective randomized trials are necessary to determine the impact of adjuvant chemotherapy for locally advanced rectal cancer.
Authors: Vincenzo Valentini; Ruud G P M van Stiphout; Guido Lammering; Maria Antonietta Gambacorta; Maria Cristina Barba; Marek Bebenek; Franck Bonnetain; Jean-Francois Bosset; Krzysztof Bujko; Luca Cionini; Jean-Pierre Gerard; Claus Rödel; Aldo Sainato; Rolf Sauer; Bruce D Minsky; Laurence Collette; Philippe Lambin Journal: J Clin Oncol Date: 2011-07-11 Impact factor: 44.544
Authors: C A Maurer; P Renzulli; C Kull; S A Käser; L Mazzucchelli; A Ulrich; M W Büchler Journal: Ann Surg Oncol Date: 2011-02-05 Impact factor: 5.344
Authors: C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; P J Goodman; J S Ungerleider; W A Emerson; D C Tormey; J H Glick Journal: N Engl J Med Date: 1990-02-08 Impact factor: 91.245
Authors: Hamid Nasrolahi; Sepideh Mirzaei; Mohammad Mohammadianpanah; Ali Mohammad Bananzadeh; Maral Mokhtari; Mohammad Reza Sasani; Ahmad Mosalaei; Shapour Omidvari; Mansour Ansari; Niloofar Ahmadloo; Seyed Hasan Hamedi; Nezhat Khanjani Journal: Ann Coloproctol Date: 2019-10-31
Authors: Elizabeth Alwers; Lina Jansen; Jakob Kather; Efrat Amitay; Hendrik Bläker; Matthias Kloor; Katrin E Tagscherer; Wilfried Roth; Esther Herpel; Jenny Chang-Claude; Hermann Brenner; Michael Hoffmeister Journal: Int J Colorectal Dis Date: 2020-09-19 Impact factor: 2.571
Authors: Hang Zhang; Ya Huang; Ge Sun; Kuo Zheng; Zheng Lou; Xian-Hua Gao; Li-Qiang Hao; Lian-Jie Liu; Rong-Gui Meng; Wei Zhang Journal: Ann Transl Med Date: 2020-06